Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00674739 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts
A Phase 3 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 470
- Enrollment target
NCT00674739 is a Phase 3 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 470 participants.
The verdict
NCT00674739, a Phase 3 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 470 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the creams. External genital and perianal warts are caused by the infection of human papillomavirus or HPV. HPV infection is a sexually transmitted disease (STD). External genital warts look like small flesh-colored, pink, or red growths on or around the external skin of sex organs or perianal area. The warts may look similar to the small parts of a cauliflower or they may be very tiny and difficult to see. They often appear in clusters of three or four, and may grow and spread rapidly. They usually are not painful, although they may cause mild pain, bleeding, and itching.
Interventions
- DRUG Imiquimod
- DRUG placebo cream
- DRUG 3.75% imiquimod cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00674739
The ClinicalTrials.gov registry entry for NCT00674739 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Imiquimod is the first listed.
NCT00674739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00674739 about?
NCT00674739 is a clinical study titled "Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts". The purpose of this study is to determine whether imiquimod creams are effective in treating external genital warts (EGW). The secondary objective of this study is to provide information on recurrence of EGW. Additionally the study will also look at any adverse events associated with the use of the ...
What is the current status of trial NCT00674739?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 470 participants. The study started on 2008-05. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00674739?
The interventions under investigation include: Imiquimod (DRUG), placebo cream (DRUG), 3.75% imiquimod cream (DRUG).
Who is sponsoring clinical trial NCT00674739?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.